Drug Detail:Deucravacitinib (Deucravacitinib (due krav a sye ti nib))
Drug Class: Multikinase inhibitors
Drug Detail:Deucravacitinib (Deucravacitinib (due krav a sye ti nib))
Drug Class: Multikinase inhibitors
No information is available on the use of deucravacitinib during breastfeeding. Because it is more than 80% bound to plasma proteins, the amount in milk is likely to be low. However, it is well absorbed orally. If deucravacitinib is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Relevant published information was not found as of the revision date.
Relevant published information was not found as of the revision date.
(Psoriasis) Adalimumab, Etanercept, Infliximab, Phototherapy, Tretinoin
Deucravacitinib
1609392-27-9
Breast Feeding
Lactation
Milk, Human
Dermatologic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Tyrosine Kinase Inhibitors
Signal Transduction Inhibitors
Janus Kinase Inhibitors
JAK Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.